Norbuprenorphine

Formed through N-dealkylation by CYP3A4, norbuprenorphine is the primary active metabolite of buprenorphine and is included alongside the parent drug in comprehensive medication-assisted treatment (MAT) monitoring panels. Laboratory testing applications include opioid use disorder treatment program compliance monitoring, pain management testing, forensic toxicology investigations, postmortem toxicology, and clinical toxicology assessments, where detecting both buprenorphine and norbuprenorphine helps confirm actual medication ingestion rather than specimen adulteration. UTAK’s Pain Management and Pain Management Plus panels contain norbuprenorphine in lyophilized urine and whole blood matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods used in addiction medicine and clinical laboratories. Stock and custom QC solutions can incorporate buprenorphine, norbuprenorphine glucuronide, and other related opioids such as methadone, fentanyl, morphine, oxycodone, and additional pain management analytes to support comprehensive medication-assisted treatment and drugs of abuse QC programs.